New Study Shows Pfizer’s Paxlovid Pill Causes Deadly Blood Clots – Media Blackout

A new study has found that Pfizer’s Paxlovid COVID-19 pill causes adverse reactions in patients, including deadly blood clots.

Pfizer’s Paxlovid, which contains the drugs nirmatrelvir and ritonavir (NMVr), interacts with several other drugs routinely used to treat cardiovascular disease, according to a study published in the Journal of the American College of Cardiology on Wednesday. reports: Most of the concerns about drug interactions come from ritonavir, experts said.

“Co-administration of NMVr with medications commonly used to manage cardiovascular conditions can potentially cause significant drug-drug interactions and may lead to severe adverse effects,” according to the reviewed paper.

Daily Mail reported:

Dr. Houman Hemmati, Chief Medical Officer of Vyluma, Inc, shared his insights on the study and claimed that people who took Paxlovid are part of the clinical trials.

“The problem is that Paxlovid didn’t have these lengthy phase one, two, and three trials. It was rushed to market under an emergency use authorization, never an approval. And as a result, they’ve skipped a lot of these studies. And so what we’re learning about that drug and its safety is largely based on post-marketing data. What does that mean? It’s people who are actually getting it in the real life, in real-world usage, and then we find out through them,” Hemmati said.

Watch the video below:

It can be recalled that Dr. Jill tested positive for Covid AGAIN  in a ‘rebound’ case after taking Paxlovid earlier in August.

When President Joe Biden, 79, tested positive for Covid and started Paxlovid in July, Joe Biden’s doctor said he had stopped heart medications for Biden’s atrial fibrillation and high cholesterol due to his prescribing Paxlovid to treat Biden’s COVID infection. Atrial fibrillation can cause strokes and is treated by blood thinners to reduce the risk of stroke-causing blood clots being formed.

Be the first to comment

Leave a Reply

Your email address will not be published.